IPO registrations (S-1, F-1) · Registrants
Landos Biopharma, Inc.
- SEC CIK
- 1785345 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-01-13, last 2021-02-01; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2021-02-04; declared effective 2021-02-03
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1800 KRAFT DRIVE, SUITE 216, Blacksburg, VA 24060
- EIN
- 81-5085535
- EDGAR entity type
- operating
- Insiders and CEO pay
- Landos Biopharma, Inc. on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per share (S-1/A filed 2021-02-01)
- Final price
- $16.00 per share, within the range (424B4 filed 2021-02-04, an initial public offering)
- Shares sold
- 6,250,000
- Gross proceeds
- $100,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol LABP
- Lead underwriters
- J.P. Morgan; Jefferies; Leerink Partners
- Syndicate
- Raymond James
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Landos Biopharma, Inc. Fuzzy (name and state)
- Form 5500 plan sponsor: LANDOS BIOPHARMA, INC. EXACT (EIN (EXACT))
- Federal award recipient: LANDOS BIOPHARMA, INC. Fuzzy (name and state)
- Form D issuer: Landos Biopharma, Inc. EXACT (CIK (EXACT))
- SEC filer: Landos Biopharma, Inc. EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-01-13 | S-1 | S-1 (registration) | Landos Biopharma, Inc. | 0001193125-21-008210 ↗ |
| 2021-01-28 | S-1/A | S-1/A (amendment) | Landos Biopharma, Inc. | 0001193125-21-020102 ↗ |
| 2021-02-01 | S-1/A | S-1/A (amendment) | Landos Biopharma, Inc. | 0001193125-21-024746 ↗ |
| 2021-02-03 | EFFECT | EFFECT (declared effective) | Landos Biopharma, Inc. | 9999999995-21-000415 ↗ |
| 2021-02-04 | 424B4 | 424B4 (final prospectus) | Landos Biopharma, Inc. | 0001193125-21-028952 ↗ |
| 2022-08-15 | EFFECT | EFFECT (declared effective) | Landos Biopharma, Inc. | 9999999995-22-002380 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-02-01 | S-1/A | registration statement | $15.00–$17.00 | 6,250,000 | - | Nasdaq LABP | 4 | primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 4 | document ↗ | |
| 2021-02-04 | 424B4 | final prospectus | $16.00 | 6,250,000 | $100,000,000 | Nasdaq LABP | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bassaganya-Riera Josep | Director,Officer,TenPercentOwner; TenPercentOwner | Chairman, President and CEO | 11 | 2021–2023 | |
| Chauhan Jyoti | Officer | ED, Global Clinical Operations | 3 | 2021 | |
| Colombel Jean-Frederic | Director | 1 | 2021 | ||
| EDELMAN JOSEPH | Director; Director,TenPercentOwner; TenPercentOwner | 5 | 2021–2023 | ||
| Garabedian Christopher Nishan | Director | 5 | 2021–2024 | ||
| Hontecillas Raquel | Officer | Chief Scientific Officer | 2 | 2021 | |
| PERCEPTIVE ADVISORS LLC | Director,TenPercentOwner; TenPercentOwner | 5 | 2021–2023 | ||
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director; Director,TenPercentOwner; TenPercentOwner | 5 | 2021–2023 | ||
| Perceptive Xontogeny Venture Fund, LP | Director; Director,TenPercentOwner; TenPercentOwner | 5 | 2021–2023 | ||
| Poukalov Konstantin | Director,TenPercentOwner | 3 | 2021 | ||
| WONG RODERICK | Director; Director,TenPercentOwner; TenPercentOwner | 3 | 2021–2022 | ||
| Xontogeny, LLC | Director; Director,TenPercentOwner | 4 | 2021 | ||
| RTW INVESTMENTS, LP | TenPercentOwner | 3 | 2021–2022 | ||
| Girao Tiago | Director | 6 | 2021–2024 | ||
| MAYLEBEN TIMOTHY M | Director; Director,Officer | Interim CEO | 6 | 2021–2024 | |
| Callori Fred | Director | 6 | 2021–2024 | ||
| BITAR PATRICIA L | Officer | Interim CFO | 2 | 2021 | |
| Adsett Roger | Director | 5 | 2022–2024 | ||
| Truesdell Patrick | Officer | Vice President and Controller | 2 | 2022–2023 | |
| Oakes Gregory | Director,Officer | Chief Executive Officer | 5 | 2022–2024 | |
| Cataldi Fabio | Officer | Chief Medical Officer | 5 | 2022–2024 | |
| Perceptive Xontogeny Venture Fund II, LP | TenPercentOwner | 1 | 2023 | ||
| Batycky Alka | Director | 3 | 2023–2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-08-23 | Landos Biopharma, Inc. | Biotechnology | $60,259,063 | $60,259,063 | 10 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Landos Biopharma, Inc. | VA | State business registries | name and state |
| Federal award recipient | LANDOS BIOPHARMA, INC. | VA | Federal spending (USAspending) | name and state |
| Form D issuer | Landos Biopharma, Inc. | VA | Form D private offerings | CIK (EXACT) |
| Patent assignee | LANDOS BIOPHARMA, INC. | VA | Patents (USPTO) | name and state |
| SEC filer | Landos Biopharma, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Landos Biopharma, Inc | VA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | LANDOS BIOPHARMA, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, VA first:
- Osteologix, Inc. VA
- NEW RIVER PHARMACEUTICALS INC VA
- Quoin Pharmaceuticals Ltd. VA
- Aditxt, Inc. VA
- Retension Pharmaceuticals, Inc. VA
- MorphoSys AG 2M
- Affimed N.V. 2M
- InflaRx N.V. 2M
- Biofrontera AG 2M
- CURAXIS PHARMACEUTICAL Corp 2Q
In other datasets, the same topic (Health) in VA:
- Nonprofit: ABSTINENCE EDUCATION OF VIRGINIA (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health